PharmaVoice 100s: Standout execs

Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.

By Meagan Parrish • Sept. 25, 2023

For Astellas’ CMO, accelerating innovation means working at the edge of your comfort zone

Scientific discovery through new, breakthrough modalities is essential to solve current and future global health challenges – but the path is not easy nor well-defined.

Sept. 25, 2023

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

By Michael Gibney • Sept. 15, 2023

Catching up with 2022 PharmaVoice 100 honorees

Tapping into our growing community for expertise and inspiration.

By Meagan Parrish • Sept. 13, 2023

A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups

The biotech’s chief financial officer Robert Landry is retiring in February.

By Karissa Waddick • Sept. 12, 2023

Ex-Sanofi executive Sibold joins Madrigal as new CEO

Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.

By Ned Pagliarulo • Sept. 11, 2023

‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.

By Michael Gibney • Sept. 7, 2023

Pharma faces a slew of leadership shakeups

Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.

By Karissa Waddick • Sept. 7, 2023

Roz Brewer announces sudden departure as CEO of Walgreens

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

By Meagan Parrish • Sept. 1, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

How an AstraZeneca exec is leading the charge in the next immuno-oncology era

The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

By Michael Gibney • Aug. 17, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

By Meagan Parrish • Aug. 11, 2023

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

By Michael Gibney • Aug. 8, 2023

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

By Karissa Waddick • Aug. 7, 2023

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

By Michael Gibney • Aug. 3, 2023

Biogen’s layoffs are the latest in an industrywide slip

Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.

By Karissa Waddick • July 26, 2023

A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

By Taren Grom and Meagan Parrish • July 20, 2023

What the 2014 Ebola outbreak taught this biotech CEO about persuasion

A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

By Alexandra Pecci • July 18, 2023

Flagship, PhRMA prioritize experience in hot summer exec changes

With major projects brewing at both organizations, these new leaders will hit the ground running. 

By Karissa Waddick • July 14, 2023

A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

By Alexandra Pecci • July 11, 2023

The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

A pharma summer — how leaders unwind and recharge their teams in the warmer months

Vacation is calling, but so are patients. Here's how the industry adjusts in the summer. 

By Michael Gibney • June 30, 2023

How Sanofi is taking a ‘creative’ approach to dealmaking

Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.

By Taren Grom • June 23, 2023